Universität zu Köln

Grzella, Anne-Nele, Schleicher, Sabine, Shah-Hosseini, Kija ORCID: 0000-0001-9616-6942, Astvatsatourov, Anatoli, Raskopf, Esther, Allekotte, Silke and Moesges, Ralph (2019). Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing. Int. Arch. Allergy Immunol., 179 (2). S. 123 - 132. BASEL: KARGER. ISSN 1423-0097

Full text not available from this repository.

Abstract

Background: Liposomal eye spray (LS) has been introduced for the treatment of dry eye. Whether LS can also relieve symptoms due to allergic rhinoconjunctivitis (ARC) has not yet been sufficiently investigated. Objectives: The aim of this study was to assess the onset of action, the reduction of allergy symptoms, and the safety of LS - a nonpharmacological treatment option - compared with those of antihistamine eye drops (AD). Methods: In this open, prospective, controlled, monocenter noninterventional study, adults with ARC received either LS or AD for the relief of eye irritation after a positive conjunctival provocation test (CPT). All patients completed a questionnaire before and after the CPT. Eye irritation was rated on a visual analogue scale (VAS) at 6 time points. Conjunctival redness was analyzed using objective digital analysis based on images taken during the study visit. Results: Data were collected from 40 patients (20 per group). In both groups, 80% of patients perceived an onset of action within 0-2 min after application of LS or AD following the CPT. Relief of eye irritation (as determined by VAS) increased throughout the visit for both groups. In the digital analysis, the mean proportion of redness of the eye decreased from 10.3 to 7.0% for LS and from 10.4 to 6.5% for AD, with the largest difference observed 10 min after application (LS: 8.9%; AD: 6.0%; p = 0.094). Conclusions: LS is a nonpharmacological treatment option for ARC, showing no significant difference or relevant numerical inferiority to AD in any parameter studied. It was generally safe and well tolerated. (C) 2019 S. Karger AG, Basel

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Grzella, Anne-Nele UNSPECIFIED UNSPECIFIED UNSPECIFIED Schleicher, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Shah-Hosseini, Kija UNSPECIFIED orcid.org/0000-0001-9616-6942 UNSPECIFIED Astvatsatourov, Anatoli UNSPECIFIED UNSPECIFIED UNSPECIFIED Raskopf, Esther UNSPECIFIED UNSPECIFIED UNSPECIFIED Allekotte, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, Ralph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-138796
DOI:	10.1159/000496938
Journal or Publication Title:	Int. Arch. Allergy Immunol.
Volume:	179
Number:	2
Page Range:	S. 123 - 132
Date:	2019
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	1423-0097
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language THERAPY CONCEPT; LEVOCABASTINE; GUIDELINES; RHINITIS; PREVALENCE; EFFICACY; IMPACT Multiple languages Allergy; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13879